Tavexia Lifecare Ltd has announced a board-authorized move to explore a 60% stake acquisition in Meyonex Pharmaceuticals. Alongside this growth strategy, the company has appointed M/s DEVAM & Associates LLP as its new statutory auditor following the resignation of M/s SSRV & Associates. Shareholders should note the upcoming AGM scheduled for late September and the re-appointment of an independent director, marking a period of board-level transition and strategic expansion.
Tavexia Lifecare Eyes Inorganic Growth and Overhauls Auditor Board
- Acquisition target: Up to 60% stake in Meyonex Pharmaceuticals Limited.
- Auditor transition: M/s DEVAM & Associates LLP appointed as new Statutory Auditor.
Reader Takeaway: Acquisition signal shows intent to expand, while new auditor appointment brings a fresh governance cycle under scrutiny.
What just happened
Tavexia Lifecare’s board has greenlit a strategic exploration of acquiring up to 60% equity in Meyonex Pharmaceuticals Limited. Directors Chirag Deepak Dedhia and Sachin Bhanubhai Manseta are tasked with leading due diligence and valuation discussions. Simultaneously, the company is rotating its statutory audit firm; M/s SSRV & Associates has resigned effective September 07, 2026, with M/s DEVAM & Associates LLP slated to take over for a five-year term, pending shareholder approval at the upcoming 46th Annual General Meeting (AGM).
Why this matters
The move into Meyonex Pharmaceuticals suggests Tavexia is looking to bolster its position in the pharmaceutical space through inorganic growth. Investors should watch the valuation and deal structure, which remain in early, exploratory stages. The change in auditors is a significant governance event that shareholders typically monitor closely for continuity and transparency.
Corporate Governance Updates
Beyond the auditor transition, the board approved the re-appointment of Mrs. Khushboo Vasudev as an Independent Director for a second five-year term beginning December 31, 2026. The company also set the timeline for its 46th AGM, with the register of members and transfer books scheduled to remain closed from September 24 to September 30, 2026.
What to track next
Investors should monitor future BSE filings for definitive agreements regarding the Meyonex acquisition. Key details regarding the purchase price, funding, and potential impact on Tavexia’s balance sheet will be critical for assessing the long-term value of this transaction.